Introduction {#s0001}
============

Phaeochromocytomas (PCCs) and paragangliomas (PGLs) are rare catecholamine-producing neuroendocrine tumors (NETs) deriving from adrenal (PCC) or extra-adrenal (PGL) chromaffin tissue.[@cit0001]

Surgical resection, the mainstay of treatment in PCC/PGL, is curative in most patients. However, almost 20% of tumors are malignant with the potential to recur and spread systemically, with negative implications for prognostic outlook.[@cit0002]

Treatment options for metastatic PCC/PGL are limited to radionuclide[@cit0003] and cytotoxic chemotherapy, the efficacy of which mostly relies on retrospective reports of small numbers of patients.[@cit0005] Systemic chemotherapy may control disease progression[@cit0006] but does not prolong survival.[@cit0007] Because of these major shortcomings in managing metastatic PCC/PGL, 5-year survival rates are \<50%[@cit0008] and inferior to those seen in other metastatic NETs.[@cit0009]

Therapeutic inhibition of the programmed cell death (PD-1) receptor-ligand immune checkpoint has recently revolutionised the systemic treatment of malignancy.[@cit0010]

By antagonising the immune-suppressive interaction between PD-1, a T-cell co-inhibitory receptor, and its ligand PD-L1, therapeutic antibodies against this pathway can restore an efficacious anti-tumor immune response, manifest as durable clinical responses in a proportion, but not all patients.[@cit0011]

Identification of biologic predictors of response is therefore a priority in attempting to develop immunotherapy, more so for rare malignancies where enrichment of molecularly phenotyped patient populations with enhanced potential to respond to treatment is highly desirable in clinical trial design.

PD-L1 expression by immunohistochemistry has been advocated as a putative predictive correlate of response to anti-PD-1 therapies and incorporated as a biomarker in clinical studies since initial early-phase trials of immune-checkpoint inhibitors.[@cit0012]

While the stratifying potential of PD-L1 is imperfect because of significant clinical responses having been observed in PD-L1 negative tumors,[@cit0013] its use has expanded in certain malignancies where prospective data has correlated high PD-L1 expression with longer progression-free and overall survival following immune-checkpoint inhibition.[@cit0014]

More recently, tumor cell expression of PD-L2, an important modulator of T-helper 2 cell responses[@cit0015] has been independently correlated with the efficacy of PD-1 axis targeted inhibitors suggesting that the diversity in PD ligands expression might contribute to the heterogeneity of clinical responses to checkpoint inhibitors.[@cit0016]

Biologically, elevated PD-L1 expression within tumor cells or the surrounding microenvironment is dynamic as a result of various molecular events including hypoxia[@cit0017] and similar correlations have been highlighted for PD-L2.[@cit0018] We have previously shown that activation of hypoxia inducible factor 1α (Hif-1α) is a key molecular hallmark in the metastatic progression of PCC/PGL,[@cit0019] a disease where constitutive Hif-1α stabilization secondary to mitochondrial dysfunction, termed "pseudo-hypoxia," is a key pathophysiological trait.[@cit0020]

In a disease where the anti-cancer immune response has remained largely unexplored, we hypothesized that activation of the hypoxic response might promote cancer-specific immune-tolerance through expression of PD ligands and thus facilitate malignant progression in PCC/PGL. To test this hypothesis, and attempt to qualify novel targets for immunotherapy, we evaluated the prevalence and clinico-pathologic significance of PD-L1 and PD-L2 expression in a well-annotated series of PCC/PGL.

Materials and methods {#s0002}
=====================

Patient characteristics {#s0002-0001}
-----------------------

We included 100 consecutive PCC/PGL patients who underwent surgical treatment at Imperial College, a tertiary referral center with a specialist NET board, from 1983--2011. Haematoxylin and eosin (H&E) slides were reviewed to identify relevant pathological features and archival paraffin-embedded samples were retrieved.

Clinico-pathologic data, including tumor characteristics and survival, was gathered from medical records. Follow-up was updated prospectively and censored in November 2016. Malignant behavior was defined as detection of metastasis to lymph nodes or distant sites either at diagnosis or during subsequent review. Ethical approval was granted by the Imperial College Tissue Bank (Ref. R14066--2A).

Tissue microarrays (TMAs) and immunohistochemistry (IHC) {#s0002-0002}
--------------------------------------------------------

TMA blocks were prepared as described previously.[@cit0021] All the samples utilised were surgical specimens. No biopsies were included. One mm tumor cores were sampled in triplicate using a MTA-1 Manual Tissue Microarrayer (Beecher Instruments, USA). IHC staining was performed on 5μm sections using the Leica Bond RX stainer (Leica, Buffalo, IL).

The primary antibodies anti-PD-L1 (Clone E1L3N; Cell Signaling Cat. Nr. 13684), anti-PD-L2 (Sigma Aldrich, Cat. Nr. 3500395) were incubated overnight at the concentration 1:100 and 1:300, respectively as described before.[@cit0022] IHC staining for biomarkers of hypoxia/angiogenesis including VEGF-A (Cat. Nr. Sc- 152; Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), Hif-1α (Cat. Nr. Ab8366 AbCam, Cambridge, UK) and CaIX (Cat. Nr. NB100--417, Novus Biologicals, Cambridge, UK) followed described previously methodology.[@cit0021] Sections were incubated for 1 hour at room temperature with the secondary antibody and processed using the Polymer-HRP system (BioGenex, Fremont, CA, USA), developed in diaminobenzidine and counterstained in Mayer\'s Haematoxylin.

Biomarker expression was scored independently by 2 histopathologists (FAM, RED) using a semi-quantitative immuno-histoscore (IHS). For clinicopathologic correlation, continuous IHS ranging from 0--300 were categorised around the median of the distribution. Accounting for the focal pattern of PD-L1 expression cases displaying moderate intensity of signal in ≥5% of tumor cells were considered positive.[@cit0022]

Gene set enrichment analysis (GSEA) {#s0002-0003}
-----------------------------------

To characterize signaling pathways associated with PD-ligands expression we performed GSEA using RNA-sequencing data from the TCGA cohort of PCC/PGL (n = 184). PD-L1 (CD274) and PD-L2 (PDCD1LG2) were used as phenotypic labels. Analyzed gene sets included validated hallmark signatures derived from the MSigDB database to reflect the hypoxic response and a variety of transcriptional programs involved in anti-cancer immunity including the inflammatory response, the IL-6/JAK/STAT3 pathway, IL-2/STAT5 pathway, and signatures relating to Interferon-γ, IFN-α, Tumor Necrosis Factor a (TNF-α) and Transforming-Growth Factor β (TGF-β). We evaluated enrichment in phenotype both in positive and negative correlation with PD-L1 and PD-L2.

Using cBioportal (<http://www.cbioportal.org>, accessed 23/03/2017) we examined the 20 genes displaying the strongest positive correlation with PD ligands by Pearson\'s correlation index. Using oncoprint analysis we evaluated PD ligands expression in relationship to the presence of mutations in key susceptibility loci for PCC/PGL including Succinate-Dehydrogenase (SDH) subunits A-D, Von-Hippel Lindau (VHL), Neurofibromatosis-1 (NF-1) and c-RET.

Statistical analysis {#s0002-0004}
--------------------

Pearson\'s χ^2^ or Fisher\'s exact tests (2-tailed) were used to test for any significant associations between variables as indicated. A *p* value of \<0.05 was used as a threshold for statistical significance. Kaplan-Meier curves were used for survival analyses. IBM SPSS version 23 (SPSS inc., Chicago, IL, USA) was used for all statistical analysis.

Results {#s0003}
=======

Patient characteristics {#s0003-0001}
-----------------------

The clinico-pathologic features of the patient cohort are displayed in ([Table 1](#t0001){ref-type="table"}). Patients were followed up over a median period of 4.7 y (range 6 months -- 34 years). Median age at diagnosis was 40 y. Malignant disease was identified radiologically or histologically in 10 patients as either *de novo* metastatic presentation (n = 3) or systemic recurrence during follow-up (n = 7). Twenty-nine patients had syndromic PCC/PGL based on germline DNA testing: the most prevalent mutation was in the RET proto-oncogene (n = 13) followed by mutation in one of the SDH subunits (n = 11), VHL (n = 3), NF-1 (n = 2). The most prevalent genotype in malignant cases was mutation in SDH-B (n = 2) followed by VHL (n = 1) and NF-1 (n = 1). Table 1.Clinical characteristics of patients with PCC/PGL.Baseline characteristicn = 100Gender  Male46 Female54Age (years)  \<4050 ≥ 4050Disease Site  PCC monolateral59 PCC bilateral5 PGL (Extra-adrenal)36Maximum tumor diameter  \< 5 cm70 ≥ 5 cm30Behavior  Benign90 Malignant10Catecholamine secretion  Noradrenaline54 Adrenaline28 Dopamine15 Silent20 Missing13Tumor Necrosis  Absent76 Present16Capsular Invasion  Absent79 Present13Vascular Invasion  Absent84 Present8Genotype (germline mutations)  SDH-B9 SDH-D2 NF-12 VHL3 RET12

All patients had surgery as the principal treatment of their tumor. Six patients with metastatic disease received radiotherapy, 2 received chemotherapy, and 4 received Iodine-131-meta-iodobenzylguanidine therapy.

PD ligands expression in PCCs/PGLs {#s0003-0002}
----------------------------------

In total, 18 cases stained positively for PD-L1 according to the pre-specified cut-off. PD-L1 staining was focal, with a cytoplasmic and membranous pattern of immunopositivity as shown in [Fig. 1A](#f0001){ref-type="fig"}. The prevalence of PD-L1 immunopositivity was 40% in malignant (4/10) and 15% (14/90) in benign cases (Fisher\'s Exact test p = 0.08). There was no significant association between PD-L1 positivity and any of the salient clinico-pathologic features including type of underlying germline mutation, tumor size, tumor localization (adrenal vs. extra-adrenal). Figure 1.Representative sections of PCC/PGL TMA cores. Panel (A)shows focal expression of PD-L1 in a malignant case and the diffuse pattern of immunopositivity typical of PD-L2 immunostaining (Panel B). Panel (B) highlights the specificity of PD-L2 staining for PCC/PGL cells where sustentacular cells are negative for PD-L2 expression. Panels C and D show Kaplan-Meier curves describing the overall survival of patients with PCC/PGL categorized according to PD-L1 (Panel C) and PD-L2 (Panel D).

We identified PD-L2 expression in 16 cases, where the pattern of immunopositivity observed was cytoplasmic and diffuse ([Fig. 1B](#f0001){ref-type="fig"}). The median PD-L2 IHS was 100 (mean 146, range 60--300). PD-L2 expression was positively associated with malignant behavior. Prevalence of PD-L2 expression was 50% in malignant cases (5/10) compared with 12% in benign specimens (11/90, Pearson Chi-square p = 0.002). The proportion of PD-L2 positivity was higher in vasculo-invasive PCC/PGL (5/7 cases, 71% vs. 11/84, 13%, p \< 0.001). Similarly, we found a higher rate of PD-L2 immunopositivity in cases displaying capsular invasion (6/13, 46% vs. 10/79, 13%, p = 0.003) and necrosis (7/16, 44% vs. 9/76, 12%, p = 0.002). We found evidence of PD-L1 and PD-L2 co-immuno expression in 3 cases, with a positive association with malignancy (1/89 cases vs. 2/10, Fisher Exact test p = 0.02).

A total of 26 samples showed high CaIX expression levels (median IHS 200, mean 178, range 75--275) whereas VEGF-A was overexpressed in 64 (median IHS 200, mean 178, range 75--275) and Hif-1α in 35 (median IHS 120, mean 107, range 0--300) (Supplementary Fig. S1).

We evaluated the relationship between the expression of biomarkers of hypoxia and angiogenesis and PD ligands. As shown in [Fig. 2A--B](#f0002){ref-type="fig"}, PD-L1-positive PCC/PGL were characterized by higher Hif-1α (median IHS 200 vs. 100, Mann Whitney U = 396.0, p = 0.01) but not CaIX. Figure 2.The relationship between PD ligands and the expression of Hif-1α (Panel A), CaIX (Panel B) and VEGF-A (Panel C). Expression of candidate biomarkers is quantified using an immuno-histoscore (IHS). Median values (+/− interquartile ranges) are presented. An asterisk (\*) highlights a statistically significant difference in median IHS values resulting from a Mann-Whitney U test.

Similarly, PD-L2 overexpressing tumors had a higher proportion of Hif-1α (median IHS 166 vs. 100, Mann Whitney U = 407.0, p = 0.01) and CaIX overexpression (median IHS 33 vs. 200, Mann Whitney U = 280.0, p \< 0.001). We found no relationship between PD ligands and VEGF-A expression ([Fig. 2C](#f0002){ref-type="fig"}).

PD-L1 and PD-L2 expression: relationship with malignancy and survival {#s0003-0003}
---------------------------------------------------------------------

We evaluated the prognostic value of PD-L1 and PD-L2 expression in the whole study population where mean OS was 25 y (95% CI 12--29 years) and median OS was not reached. OS was significantly shorter in malignant cases where mean OS was 7.2 y (2.2--12.3 years) and median OS was 3.6 y (95%CI 1.2--6 years, Log-rank p \< 0.001).

The expression of PD-L1 was not predictive of OS in the entire patient population, with PD-L1 positive cases not differing from PD-L1 negative counterparts ([Fig. 1C](#f0001){ref-type="fig"}). When considering PD-L2 expression, we found that in patients overexpressing PD-L2 OS was significantly shorter with a median of 13.5 y (95%CI 8--19 years) compared with 25 y of patients with PD-L2 negative PCC/PGL (95%CI 20--30 years, Log-rank p = 0.029, [Fig. 1D](#f0001){ref-type="fig"}).

Other prognostic factors included presence of vascular invasion, capsular invasion and necrosis (Supplementary Fig. S2, Supplementary Table S1).

Differential relationship between PD-L1, PD-L2 and hypoxia: validation in TCGA data set {#s0003-0004}
---------------------------------------------------------------------------------------

We used the PCC/PGL TCGA data set to validate the relationship between PD-L1 and 2 expression and hallmarks of hypoxia. Consistent with our immunohistochemical findings, we found enrichment of transcripts involved in the hypoxic response in relationship with PD-L2 but not PD-L1 expression ([Fig. 3A](#f0003){ref-type="fig"}, Supplementary Tables S2 and S3). Figure 3.Panel A illustrates the enrichment plots for 8 hallmark signatures positively correlating with PD-L2 (PDCD1LG2) expression in the PCC/PGL TCGA data set (n = 184). Panel B illustrates the relationship between PD-L1 and 2 expression and functionally relevant genomic alterations in 6 major susceptibility loci for familial PCC/PGL (SDH subunits A-D, VHL, NF-1 and RET). Panel C illustrates linear regression analysis correlating PD-L2 expression with a panel of genes reflecting immune-exhausted T cell responses including CD4, IL10RA, HLA-DRA, IL2RA, HAVCR2 (Tim-3), ICOS, CTLA-4, BTLA, TGFB1, CD80.

We addressed mutational status in key susceptibility loci for PCC/PGL as a potential confounder, demonstrating a lack of enrichment for PD-ligand overexpression in tumor samples harbouring mutations in any of the tested loci ([Fig. 3B](#f0003){ref-type="fig"}).

Immuno-biologic qualification of PD-L1 and PD-L2 in PCC/PGL {#s0003-0005}
-----------------------------------------------------------

Using GSEA we found PD-L2 overexpressing PCC/PGL to be strongly enriched in transcriptional programs innate and adaptive anti-cancer immunity ([Fig. 3A](#f0003){ref-type="fig"}). Conversely, none of the gene sets were significantly enriched in PD-L1 overexpressing PCC/PGL, where we found a trend toward a positive association with a subset of 96 genes involved in protein secretion (nominal p = 0.03, FDR = 1) (Supplementary Table S1).

We confirmed differential gene expression profiles in correlation with PD ligands with a preferential co-expression of immune-inflammatory genes in relationship with PD-L2 as opposed to PD-L1 ([Table 2](#t0002){ref-type="table"}). Given CD4 emerged as the strongest correlate to PD-L2 expression (Pearson\'s R 0.85, [Fig. 3C](#f0003){ref-type="fig"}) we phenotypically characterized T-cell enrichment revealing a significantly positive association in genes characterizing an exhausted immune response as shown in [Fig. 3C](#f0003){ref-type="fig"}. Table 2.Gene transcripts that are most strongly co-expressed in PD-L1 and PD-L2 overexpressing PCC/PGLs from the TCGA data set (n = 184).PD-L1PD-L2Gene SymbolPearson ScoreSpearman ScoreGene SymbolPearson ScoreSpearman ScoreDNAJB140.750.75CD40.850.76MAN2A10.70.62ARHGAP300.850.74PCDHAC20.70.74CTSS0.820.75PCDHAC10.680.72FERMT30.820.71ATP2B40.670.59MS4A4A0.820.78IL6ST0.670.66AOAH0.810.73OXCT10.670.65CASP10.810.81G3BP20.670.71IL10RA0.810.72MID20.670.7PLEK0.810.7THSD7A0.670.67SASH30.810.72PTPRJ0.660.57CPVL0.810.74TBC1D90.660.6C1QC0.80.72SPOPL0.650.71IL12RB10.80.66CERS60.650.69MS4A6A0.80.74STT3B0.640.6CTSC0.790.73RNASEH10.640.6FPR30.790.66ERAP10.640.59HCK0.790.73ELMOD20.640.69SECTM10.790.66ZNF1060.640.73SIGLEC10.790.67

Discussion {#s0004}
==========

The lack of effective therapies is a highly unmet need in PCC/PGLs, a rare subtype of NETs where prediction of malignant behavior has so far been elusive and novel molecular targets are at the focus of intense research efforts.[@cit0023]

Previous work has highlighted several molecular differences between benign and malignant PCC/PGL. Activation of the hypoxic response mediated by stabilization of Hifs is a highly prevalent molecular mechanism[@cit0024] contributing to malignant progression of PCC/PGL.[@cit0025]

Immune-evasion is a key hallmark of cancer progression and expression of PD ligands is a common mechanism through which tumor cells counteract immunologic clearance by negative regulation of PD-1-expressing lymphocyte populations. The presence of hypoxia-response elements (HRE) within the PD-L1 promoter region has highlighted a therapeutically attractive link between hypoxia/angiogenesis and anti-tumor immune suppression,[@cit0026] with similar mechanisms being implied in the regulation of PD-L2 expression.[@cit0027]

In our study we document for the first time differential regulation of PD ligands in PCC/PGLs, where half of the malignant cases express at least one of the PD ligands to support their potential contribution in shaping the immune-tolerogenic environment.

Interestingly, while PD-L1 did not correlate with patients\' survival, PD-L2 overexpression identified a subset of patients with poorer prognosis following radical resection. The negative impact of PD-L2 on patients\' prognosis is further corroborated by the relationship between PD-L2 status and several histopathologic hallmarks of a more aggressive disease course including vascular, capsular invasion and necrosis -- all of which were confirmed as predictors of poor outcome in our patient series.

Furthermore, in line with previously published studies in other malignancies, we found a positive correlation between Hif-1α and PD ligands expression, stronger for PD-L2 over PD-L1, a finding that we independently validated using the TCGA RNA-Seq data set.

Interestingly, PD ligands expression was not influenced by germline mutations neither in our case series nor in the TGCA data set to suggest that pseudo-hypoxic signals might not be the only drivers of PD ligands expression.[@cit0028]

This is further strengthened by the non-uniform relationship we found between PD ligands and the expression of CaIX or VEGF-A, 2 renown targets of Hif-1α, implying that the regulation of PD-ligands in the context hypoxic/pro-angiogenic signals might involve other molecular actors.[@cit0029]

Analysis of RNA-seq data portrayed more comprehensively the biologic heterogeneity characterizing the relationship between PD ligands and tumor hypoxia.

In fact, when we considered a broader subset of 200 genes involved in the hypoxic response, PD-L2 upregulation strikingly emerged as a stronger and more substantial determinant of tumor hypoxia than PD-L1, to suggest a potential mechanistic relationship between hypoxia and PD-L2-mediated anti-tumor immune control. When evaluating individual genes in more detail, we found that, while PD-L1 expression was predominantly associated with genes involved in endoplasmic reticulum trafficking and granule secretion such as DNAJB14, MAN2A1, PCDHAC1--2, the expression of PD-L2 was strongly and consistently associated with several transcripts involved in innate and adaptive immunity including CD4, IL10RA, IL12RB1 and C1QC to suggest inherent differences in their immunobiologic role ([Table 2](#t0002){ref-type="table"}).

In several oncological indications where PD-1-targeted checkpoint inhibitors have been eventually proven effective in prospective trials, the clinical efficacy of these therapies was anticipated by prior clinicopathologic studies showing a relationship between PD ligands and clinical outcome.[@cit0012] While the likelihood of response to immunotherapy cannot be directly inferred from our data, we provide evidence of differential regulation of PD-L1 and PD-L2 in our clinical samples, with diverse ramifications in terms of their clinico-pathologic significance and predictive role in influencing patients\' survival.

Interestingly, our data suggest PD-L2 to have a more predominant role than PD-L1 in shaping the immune-tolerogenic environment, given the highly significant association with key pathways involved in innate, adaptive immunity and inflammation.

The enrichment of immunologic markers suggestive of an exhausted immune response including TGF-β-related signatures and several regulatory T-cell markers (IL10RA, IL10RB, HLA-DRA) as well as immune checkpoints (Tim-3, BTLA, CTLA-4, CD80, ICOS) provides strong immunobiologic foundations to justify the relationship between PD-L2 expression and poorer prognosis in patients with PCC/PGL.

Our results therefore provide a valuable clinical rationale for the development of immune checkpoint inhibitors in a subset PCC/PGL where anti-tumor immune exhaustion is a key prognostic trait and suggests PD-L2 expression as a putative stratifying biomarker in prospective clinical studies.

We acknowledge the relatively small sample size and the rarity of malignant cases as a limitation to our study, which is unfortunately shared with most of the published work in this field.

Nonetheless, taken together, our findings support the existence of a subset of PCC/PGL with biologic bases for PD-1--mediated tumor immune evasion and highlights a potential role for immunotherapy targeting the PD-1 ligand-receptor axis. The relationship between hypoxia, malignancy and anti-tumor immune control should be further explored in prospective studies with the aim of facilitating the development of immunotherapy in this otherwise neglected disease area.
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